Friday, 23 Mar 2018

You are here

The RheumNow Week in Review – 13 January 2017

Dr. Jack Cush reviews highlights from this past week on

  1. ARTIS RA registry shows those initiating a TNFi within 5 yrs of onset double their odds of returning to work in 3 yrs
  2. ARTIS & DANBIO registries: 8703 SpA (AS, PsA) patients treated with TNFI: they do NOT have an increase risk of cancer overall; nor the 6 most common types CA
  3. Hepatosplenic T cell lymphoma: review shows this to be a very rare event with TNFi; but is more common in IBD pts (younger), receiving thiopurines.
  4. Biosimilar Inflectra priced at only a 15% discount; CMS issues payment and claims processing information
  5. There is no interaction between low dose weekly MTX and NSAIDs, PCNs or PPIs.
  6. FDA reviewing a new drug application (NDA) for the new combo drug: allopurinol + lesinurad (Ironwood Pharm) to Rx hyperuricemia and uncontrolled gout
  7. Meta-analysis of 1069 knee OA patients- intraarticular Platelet Rich Plasma (vs HA, NS) shows significantly better WOMAC pain/function scores. @12mo,
  8. Chronic PPI use associated with 74% more C difficile infections & 2.5-fold increased risk of recurrent C difficile with chronic PPI
  9. 13% of US African Americans have diabetes; but AA are seldom included in diabetes clinical trials. Whatsupwiththat?
  10. Total knee vs hemiarthroplasty show equal outcomes;more complications with bilateral total knee replacements (pt selection is critical to the success of hemiarthroplasty)
  11. 94 pts with MTX pancytopenia in elderly; 24% mortality; risk factors include age>65, sepsis + hypoalbuminemia
  12. Multiple Comorbidity Risks with Giant Cell Arteritis
  13. Do Exercise ‘Weekend Warriors’ Lower Their Risk of Death? 
  14. The IL-6 Wars 
  15. DMARDs Under Study for Secondary Prevention of Cardiovascular Events


The author has no conflicts of interest to disclose related to this subject
The author has received compensation as an advisor or consultant on this subject

Add new comment

More Like This

The RheumNow Week in Review - 23 March 2018

Dr. Jack Cush reviews the highlights from the news, journals and major meetings. New announcements and approval from the FDA; novel associations between ANCA vasculitis and thyroid disease; flare rates after arthroplasty; and pregnancy outcomes for men and women.

MMWR: Arthritis Prevalence Increases and Varies Widely

MMWR reports that In 2015, the number of adults with arthritis continued to increase; with marked geographic variability in arthritis estimates with gaps in arthritis management.

The CDC estimates that physician-diagnosed arthritis affects 54 million of adults in the United States with an annual cost of approximately $300 billion annually.

The RheumNow Week in Review - 16 March 2018

Dr. Jack Cush reviews the highlights from the news, journals and major meetings. Bigtime rheumatologic lessons with tales from intestinal crypts, the friendly skies & the hips of hockey players. Also the microbiome and lupus, benefits of ENT findings with GPA and rare risk of opportunistic infections with biologics.

The RheumNow Week in Review - 9 March 2018

Dr. Jack Cush reviews highlights, news and recent research published this past week on This week's report includes news on new regulatory changes, new indication for tofacitinib, the rise and deficits of opioids and the benefits of fish and bariatric surgery.

ACR Responds to Association Health Plans Proposed Rule

In comments submitted today to the US Department of Labor in response to its Association Health Plans (AHP) proposed rule, the American College of Rheumatology urged Administration officials to protect essential health benefits and other consumer protections that make it possible for individuals living with rheumatic diseases to access comprehensive and affordable healthcare.